Report
EUR 200.00
For Business Accounts Only
The company cut its plasma supply’21 forecast to +10%/+20% (vs. +30% previous), now expecting sales to recover in 4Q’21 (vs. 2H’21 BS(e)), which in any event would have an impact of less than -1% on the T.P. GRF will make a bigger effort in R&D (6%-7% of sales vs. 5.5% currently) and keeps its NFD/EBITDA target of
GRIFOLS: INVESTOR DAY 2021 - DELAYED RECOVERY IN SUPPLY (ANÁLISIS BANCO SABADELL)
Investor Day’21: delay in plasma supply, with little impact on the valuation. BUY.The company cut its plasma supply’21 forecast to +10%/+20% (vs. +30% previous), now expecting sales to recover in 4Q’21 (vs. 2H’21 BS(e)), which in any event would have an impact of less than -1% on the T.P. GRF will make a bigger effort in R&D (6%-7% of sales vs. 5.5% currently) and keeps its NFD/EBITDA target of
Underlying
Grifols (GRF SM)
Provider
Sabadell
Luis Arredondo
Other Reports on these Companies
Other Reports from Sabadell
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.